Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Substrate specificity of the pyrophosphohydrolase LpxH determines the asymmetry of Bordetella pertussis lipid A.

Arenas J, Pupo E, de Jonge E, Pérez-Ortega J, Schaarschmidt J, van der Ley P, Tommassen J.

J Biol Chem. 2019 May 17;294(20):7982-7989. doi: 10.1074/jbc.RA118.004680. Epub 2019 Mar 29.

PMID:
30926608
2.

Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Raeven RHM, Brummelman J, Pennings JLA, van der Maas L, Helm K, Tilstra W, van der Ark A, Sloots A, van der Ley P, van Eden W, Jiskoot W, van Riet E, van Els CACM, Kersten GFA, Han WGH, Metz B.

Mucosal Immunol. 2018 May;11(3):1009. doi: 10.1038/mi.2017.110. Epub 2018 Feb 7.

PMID:
29411776
3.

Molecular and cellular signatures underlying superior immunity against Bordetella pertussis upon pulmonary vaccination.

Raeven RH, Brummelman J, Pennings JLA, van der Maas L, Helm K, Tilstra W, van der Ark A, Sloots A, van der Ley P, van Eden W, Jiskoot W, van Riet E, van Els CA, Kersten GF, Han WG, Metz B.

Mucosal Immunol. 2018 May;11(3):979-993. doi: 10.1038/mi.2017.81. Epub 2017 Sep 20. Erratum in: Mucosal Immunol. 2018 Feb 07;:.

PMID:
28930286
4.

Th17-Mediated Cross Protection against Pneumococcal Carriage by Vaccination with a Variable Antigen.

Kuipers K, Jong WSP, van der Gaast-de Jongh CE, Houben D, van Opzeeland F, Simonetti E, van Selm S, de Groot R, Koenders MI, Azarian T, Pupo E, van der Ley P, Langereis JD, Zomer A, Luirink J, de Jonge MI.

Infect Immun. 2017 Sep 20;85(10). pii: e00281-17. doi: 10.1128/IAI.00281-17. Print 2017 Oct.

5.

Modulating endotoxin activity by combinatorial bioengineering of meningococcal lipopolysaccharide.

Zariri A, Pupo E, van Riet E, van Putten JP, van der Ley P.

Sci Rep. 2016 Nov 14;6:36575. doi: 10.1038/srep36575.

6.

Meningococcal Outer Membrane Vesicle Composition-Dependent Activation of the Innate Immune Response.

Zariri A, Beskers J, van de Waterbeemd B, Hamstra HJ, Bindels TH, van Riet E, van Putten JP, van der Ley P.

Infect Immun. 2016 Sep 19;84(10):3024-33. doi: 10.1128/IAI.00635-16. Print 2016 Oct.

7.

Phase variation of Opa proteins of Neisseria meningitidis and the effects of bacterial transformation.

Sadarangani M, Hoe CJ, Makepeace K, van der Ley P, Pollard AJ.

J Biosci. 2016 Mar;41(1):13-9.

PMID:
26949083
8.

Outer membrane vesicles as platform vaccine technology.

van der Pol L, Stork M, van der Ley P.

Biotechnol J. 2015 Sep;10(11):1689-706. doi: 10.1002/biot.201400395. Review.

9.

Surface display of a borrelial lipoprotein on meningococcal outer membrane vesicles.

Salverda ML, Meinderts SM, Hamstra HJ, Wagemakers A, Hovius JW, van der Ark A, Stork M, van der Ley P.

Vaccine. 2016 Feb 17;34(8):1025-33. doi: 10.1016/j.vaccine.2016.01.019. Epub 2016 Jan 19.

PMID:
26801064
10.

Biosynthetically engineered lipopolysaccharide as vaccine adjuvant.

Zariri A, van der Ley P.

Expert Rev Vaccines. 2015 Jun;14(6):861-76. doi: 10.1586/14760584.2015.1026808. Epub 2015 Mar 22. Review.

PMID:
25797360
11.

Modulation of the CD4(+) T cell response after acellular pertussis vaccination in the presence of TLR4 ligation.

Brummelman J, Helm K, Hamstra HJ, van der Ley P, Boog CJ, Han WG, van Els CA.

Vaccine. 2015 Mar 17;33(12):1483-91. doi: 10.1016/j.vaccine.2015.01.063. Epub 2015 Feb 7.

PMID:
25659267
12.

Bordetella pertussis naturally occurring isolates with altered lipooligosaccharide structure fail to fully mature human dendritic cells.

Brummelman J, Veerman RE, Hamstra HJ, Deuss AJ, Schuijt TJ, Sloots A, Kuipers B, van Els CA, van der Ley P, Mooi FR, Han WG, Pinelli E.

Infect Immun. 2015 Jan;83(1):227-38. doi: 10.1128/IAI.02197-14. Epub 2014 Oct 27.

13.

Meningitis caused by a lipopolysaccharide deficient Neisseria meningitidis.

Piet JR, Zariri A, Fransen F, Schipper K, van der Ley P, van de Beek D, van der Ende A.

J Infect. 2014 Oct;69(4):352-7. doi: 10.1016/j.jinf.2014.06.005. Epub 2014 Jun 13.

PMID:
24932738
14.

Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties.

Pupo E, Hamstra HJ, Meiring H, van der Ley P.

J Biol Chem. 2014 Mar 21;289(12):8668-80. doi: 10.1074/jbc.M114.554345. Epub 2014 Feb 3.

15.

Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.

Gaillard ME, Bottero D, Errea A, Ormazábal M, Zurita ME, Moreno G, Rumbo M, Castuma C, Bartel E, Flores D, van der Ley P, van der Ark A, F Hozbor D.

Vaccine. 2014 Feb 12;32(8):931-7. doi: 10.1016/j.vaccine.2013.12.048. Epub 2014 Jan 4.

PMID:
24397896
16.

Meningococcal serogroup Y lpxL1 variants from South Africa are associated with clonal complex 23 among young adults.

du Plessis M, Wolter N, Crowther-Gibson P, Hamstra HJ, Schipper K, Moodley C, Cohen C, van de Beek D, van der Ley P, von Gottberg A, van der Ende A.

J Infect. 2014 May;68(5):455-61. doi: 10.1016/j.jinf.2013.12.011. Epub 2014 Jan 4.

PMID:
24393652
17.

LOS oligosaccharide modification enhances dendritic cell responses to meningococcal native outer membrane vesicles expressing a non-toxic lipid A.

Jones HE, Copland A, Hamstra HJ, Cohen J, Brown J, Klein N, van der Ley P, Dixon G.

Cell Microbiol. 2014 Apr;16(4):519-34. doi: 10.1111/cmi.12231. Epub 2013 Nov 6.

18.

Expression of human CEACAM1 in transgenic mice limits the Opa-specific immune response against meningococcal outer membrane vesicles.

Zariri A, van Dijken H, Hamstra HJ, van der Flier M, Vidarsson G, van Putten JP, Boog CJ, van den Dobbelsteen G, van der Ley P.

Vaccine. 2013 Nov 12;31(47):5585-93. doi: 10.1016/j.vaccine.2013.07.069. Epub 2013 Aug 6.

PMID:
23933369
19.

Cysteine depletion causes oxidative stress and triggers outer membrane vesicle release by Neisseria meningitidis; implications for vaccine development.

van de Waterbeemd B, Zomer G, van den Ijssel J, van Keulen L, Eppink MH, van der Ley P, van der Pol LA.

PLoS One. 2013;8(1):e54314. doi: 10.1371/journal.pone.0054314. Epub 2013 Jan 23.

20.

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains.

Westdijk J, Koedam P, Barro M, Steil BP, Collin N, Vedvick TS, Bakker WA, van der Ley P, Kersten G.

Vaccine. 2013 Feb 18;31(9):1298-304. doi: 10.1016/j.vaccine.2012.12.076. Epub 2013 Jan 9.

21.

Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.

Sadarangani M, Hoe JC, Callaghan MJ, Jones C, Chan H, Makepeace K, Daniels-Treffandier H, Deadman ME, Bayliss C, Feavers I, van der Ley P, Pollard AJ.

PLoS One. 2012;7(12):e51045. doi: 10.1371/journal.pone.0051045. Epub 2012 Dec 12.

22.

Prevalence and clinical course in invasive infections with meningococcal endotoxin variants.

Rodenburg GD, Fransen F, Bogaert D, Schipper K, Groenwold RH, Hamstra HJ, Westerhuis BM, van de Beek D, van der Ley P, Sanders EA, van der Ende A.

PLoS One. 2012;7(11):e49295. doi: 10.1371/journal.pone.0049295. Epub 2012 Nov 29.

23.

Lipoarabinomannan mannose caps do not affect mycobacterial virulence or the induction of protective immunity in experimental animal models of infection and have minimal impact on in vitro inflammatory responses.

Afonso-Barroso A, Clark SO, Williams A, Rosa GT, Nóbrega C, Silva-Gomes S, Vale-Costa S, Ummels R, Stoker N, Movahedzadeh F, van der Ley P, Sloots A, Cot M, Appelmelk BJ, Puzo G, Nigou J, Geurtsen J, Appelberg R.

Cell Microbiol. 2013 Apr;15(4):660-74. doi: 10.1111/cmi.12065. Epub 2012 Nov 21.

PMID:
23121245
24.

Trichinella spiralis-secreted products modulate DC functionality and expand regulatory T cells in vitro.

Aranzamendi C, Fransen F, Langelaar M, Franssen F, van der Ley P, van Putten JP, Rutten V, Pinelli E.

Parasite Immunol. 2012 Apr;34(4):210-23. doi: 10.1111/j.1365-3024.2012.01353.x.

25.

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.

van der Ley P, van den Dobbelsteen G.

Hum Vaccin. 2011 Aug;7(8):886-90. doi: 10.4161/hv.7.8.16086. Epub 2011 Aug 1.

PMID:
21785281
26.

Association of chronic meningococcemia with infection by meningococci with underacylated lipopolysaccharide.

Brouwer MC, Spanjaard L, Prins JM, van der Ley P, van de Beek D, van der Ende A.

J Infect. 2011 Jun;62(6):479-83. doi: 10.1016/j.jinf.2011.03.010. Epub 2011 Mar 31.

PMID:
21459106
27.

Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.

Asensio CJ, Gaillard ME, Moreno G, Bottero D, Zurita E, Rumbo M, van der Ley P, van der Ark A, Hozbor D.

Vaccine. 2011 Feb 11;29(8):1649-56. doi: 10.1016/j.vaccine.2010.12.068. Epub 2011 Jan 4.

PMID:
21211579
28.

Differential effect of TLR2 and TLR4 on the immune response after immunization with a vaccine against Neisseria meningitidis or Bordetella pertussis.

Fransen F, Stenger RM, Poelen MC, van Dijken HH, Kuipers B, Boog CJ, van Putten JP, van Els CA, van der Ley P.

PLoS One. 2010 Dec 23;5(12):e15692. doi: 10.1371/journal.pone.0015692.

29.

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.

van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, Martens D, Wijffels R, van der Pol L.

Vaccine. 2010 Jul 5;28(30):4810-6. doi: 10.1016/j.vaccine.2010.04.082. Epub 2010 May 16.

PMID:
20483197
30.

The structure of Neisseria meningitidis lipid A determines outcome in experimental meningococcal disease.

Fransen F, Hamstra HJ, Boog CJ, van Putten JP, van den Dobbelsteen GP, van der Ley P.

Infect Immun. 2010 Jul;78(7):3177-86. doi: 10.1128/IAI.01311-09. Epub 2010 May 3.

31.

Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Arenas J, van Dijken H, Kuipers B, Hamstra HJ, Tommassen J, van der Ley P.

Clin Vaccine Immunol. 2010 Apr;17(4):487-95. doi: 10.1128/CVI.00423-09. Epub 2010 Jan 27.

32.

Suppression of dendritic cell maturation by Trichinella spiralis excretory/secretory products.

Langelaar M, Aranzamendi C, Franssen F, Van Der Giessen J, Rutten V, van der Ley P, Pinelli E.

Parasite Immunol. 2009 Oct;31(10):641-5. doi: 10.1111/j.1365-3024.2009.01136.x.

33.

Opa+ and Opa- isolates of Neisseria meningitidis and Neisseria gonorrhoeae induce sustained proliferative responses in human CD4+ T cells.

Youssef AR, van der Flier M, Estevão S, Hartwig NG, van der Ley P, Virji M.

Infect Immun. 2009 Nov;77(11):5170-80. doi: 10.1128/IAI.00355-09. Epub 2009 Aug 31.

34.

Naturally occurring lipid A mutants in neisseria meningitidis from patients with invasive meningococcal disease are associated with reduced coagulopathy.

Fransen F, Heckenberg SG, Hamstra HJ, Feller M, Boog CJ, van Putten JP, van de Beek D, van der Ende A, van der Ley P.

PLoS Pathog. 2009 Apr;5(4):e1000396. doi: 10.1371/journal.ppat.1000396. Epub 2009 Apr 24.

35.

Identification of a novel lipopolysaccharide core biosynthesis gene cluster in Bordetella pertussis, and influence of core structure and lipid A glucosamine substitution on endotoxic activity.

Geurtsen J, Dzieciatkowska M, Steeghs L, Hamstra HJ, Boleij J, Broen K, Akkerman G, El Hassan H, Li J, Richards JC, Tommassen J, van der Ley P.

Infect Immun. 2009 Jul;77(7):2602-11. doi: 10.1128/IAI.00033-09. Epub 2009 Apr 13.

36.

Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.

de Vries JJ, Bungener L, Ter Veer W, van Alphen L, van der Ley P, Wilschut J, Huckriede A.

Vaccine. 2009 Feb 5;27(6):947-55. doi: 10.1016/j.vaccine.2008.11.046. Epub 2008 Dec 4.

PMID:
19059296
37.

Differential activation of human and mouse Toll-like receptor 4 by the adjuvant candidate LpxL1 of Neisseria meningitidis.

Steeghs L, Keestra AM, van Mourik A, Uronen-Hansson H, van der Ley P, Callard R, Klein N, van Putten JP.

Infect Immun. 2008 Aug;76(8):3801-7. doi: 10.1128/IAI.00005-08. Epub 2008 May 19.

38.

Supplementation of whole-cell pertussis vaccines with lipopolysaccharide analogs: modification of vaccine-induced immune responses.

Geurtsen J, Fransen F, Vandebriel RJ, Gremmer ER, de la Fonteyne-Blankestijn LJ, Kuipers B, Tommassen J, van der Ley P.

Vaccine. 2008 Feb 13;26(7):899-906. doi: 10.1016/j.vaccine.2007.12.012. Epub 2007 Dec 31.

PMID:
18207288
39.

The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction.

Appelmelk BJ, den Dunnen J, Driessen NN, Ummels R, Pak M, Nigou J, Larrouy-Maumus G, Gurcha SS, Movahedzadeh F, Geurtsen J, Brown EJ, Eysink Smeets MM, Besra GS, Willemsen PT, Lowary TL, van Kooyk Y, Maaskant JJ, Stoker NG, van der Ley P, Puzo G, Vandenbroucke-Grauls CM, Wieland CW, van der Poll T, Geijtenbeek TB, van der Sar AM, Bitter W.

Cell Microbiol. 2008 Apr;10(4):930-44. Epub 2007 Dec 5.

PMID:
18070119
40.

A cross-reactive neisserial antigen encoded by the NMB0035 locus shows high sequence conservation but variable surface accessibility.

Arenas J, Abel A, Sánchez S, Marzoa J, Berrón S, van der Ley P, Criado MT, Ferreirós CM.

J Med Microbiol. 2008 Jan;57(Pt 1):80-7.

PMID:
18065671
41.

A novel secondary acyl chain in the lipopolysaccharide of Bordetella pertussis required for efficient infection of human macrophages.

Geurtsen J, Angevaare E, Janssen M, Hamstra HJ, ten Hove J, de Haan A, Kuipers B, Tommassen J, van der Ley P.

J Biol Chem. 2007 Dec 28;282(52):37875-84. Epub 2007 Oct 29.

42.
43.

Consequences of the expression of lipopolysaccharide-modifying enzymes for the efficacy and reactogenicity of whole-cell pertussis vaccines.

Geurtsen J, Vandebriel RJ, Gremmer ER, Kuipers B, Tommassen J, van der Ley P.

Microbes Infect. 2007 Jul;9(9):1096-103. Epub 2007 May 17.

PMID:
17644385
44.

A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.

van Berkel ME, Schrijver EH, van Mourik A, Tesselaar K, van der Ley P, Steeghs L, Oosterwegel MA.

Vaccine. 2007 Jun 11;25(24):4681-8. Epub 2007 Apr 25.

PMID:
17499399
45.

Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Geurtsen J, Banus HA, Gremmer ER, Ferguson H, de la Fonteyne-Blankestijn LJ, Vermeulen JP, Dormans JA, Tommassen J, van der Ley P, Mooi FR, Vandebriel RJ.

Clin Vaccine Immunol. 2007 Jul;14(7):821-9. Epub 2007 May 9.

46.

TLR4-dependent adjuvant activity of Neisseria meningitidis lipid A.

Zughaier S, Steeghs L, van der Ley P, Stephens DS.

Vaccine. 2007 May 30;25(22):4401-9. Epub 2007 Apr 2.

47.

Expression of the lipopolysaccharide-modifying enzymes PagP and PagL modulates the endotoxic activity of Bordetella pertussis.

Geurtsen J, Steeghs L, Hamstra HJ, Ten Hove J, de Haan A, Kuipers B, Tommassen J, van der Ley P.

Infect Immun. 2006 Oct;74(10):5574-85.

48.

Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications.

El Khattabi M, Adams H, Heezius E, Hermans P, Detmers F, Maassen B, van der Ley P, Tommassen J, Verrips T, Stam J.

Clin Vaccine Immunol. 2006 Oct;13(10):1079-86. Epub 2006 Aug 23.

49.

Shielding of immunogenic domains in Neisseria meningitidis FrpB (FetA) by the major variable region.

Kortekaas J, Pettersson A, van der Biezen J, Weynants VE, van der Ley P, Poolman J, Bos MP, Tommassen J.

Vaccine. 2007 Jan 2;25(1):72-84. Epub 2006 Jul 28.

PMID:
16914236
50.

A novel phase-variable autotransporter serine protease, AusI, of Neisseria meningitidis.

van Ulsen P, Adler B, Fassler P, Gilbert M, van Schilfgaarde M, van der Ley P, van Alphen L, Tommassen J.

Microbes Infect. 2006 Jul;8(8):2088-97. Epub 2006 Jun 8.

PMID:
16824779

Supplemental Content

Loading ...
Support Center